Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name NG-641
Synonyms
Therapy Description

NG-641 is an engineered oncolytic enadenotucirev adenovirus expressing a bispecific FAP-TAc T-cell activator that binds to fibroblast activating protein (FAP) on cancer associated fibroblasts and to CD3 on T-lymphocytes, as well as CXCL9, CXCL10, and IFN alpha, which potentially enhances T-cell activation and induces killing of FAP-positive tumor fibroblasts (Cancer Res 2019;79(13 Suppl):Abstract nr 5013).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
NG-641 NG 641|NG641 NG-641 is an engineered oncolytic enadenotucirev adenovirus expressing a bispecific FAP-TAc T-cell activator that binds to fibroblast activating protein (FAP) on cancer associated fibroblasts and to CD3 on T-lymphocytes, as well as CXCL9, CXCL10, and IFN alpha, which potentially enhances T-cell activation and induces killing of FAP-positive tumor fibroblasts (Cancer Res 2019;79(13 Suppl):Abstract nr 5013).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04830592 Phase I NG-641 NG-641 + Pembrolizumab A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck (MOAT) Active, not recruiting GBR 0
NCT04053283 Phase I NG-641 First in Human Study With NG-641, an Oncolytic Transgene Expressing Adenoviral Vector Active, not recruiting USA 0


Additional content available in CKB BOOST